Abstract
Hurthle cell carcinoma (HCC) of the thyroid is an uncommon and relatively rare differentiated thyroid neoplasm. To our knowledge, no reported case of adrenal metastases with abdominal carcinomatosis secondary to HCC of the thyroid has been demonstrated by F-18 FDG PET/CT imaging. One report of adrenal uptake on I-131 whole-body scan with HCC exists. In this case report, we describe a patient with HCC who had a left adrenal metastasis with abdominal carcinomatosis that was discovered using F-18 FDG PET/CT imaging.
Key words
adrenal metastasis - abdominal carcinomatosis - Hurthle cell carcinoma - PET/CT imaging
References
-
1
Azadian A, Rosen IB, Walfish PG, Asa SL.
Management considerations in Hurthle cell carcinoma.
Surgery.
1995;
118
711-714
-
2
Orsolon P, Bagni B, Geatti O, Guerra UP.
An unusual adrenal metastasis secondary to Hurthle cell carcinoma of the thyroid.
Clinical Nuclear Medicine.
1996;
21
312-315
-
3
Cooper DS, Schneyer CR.
Follicular and Hurthle cell carcinoma of the thyroid.
Endocrinology and metabolism clinics of North America.
1990;
19
577-591
-
4
Hamann A, Gratz KF, Soudah B, Fritsch RS, Georgii A, Hundeshagen H.
The clinical course of oxyphilic carcinoma of the thyroid.
Nuklearmedizin.
1992;
31
230-238
-
5
Har-El G, Hadar T, Segal K, Levy R, Sidi J.
Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy.
Cancer.
1986;
57
1613-1617
-
6
Tollefsen HR, Shah JP, Huvos AG.
Hurthle cell carcinoma of the thyroid.
American Journal of Surgery.
1975;
130
390-394
-
7
Watson RG, Brennan MD, Goellner JR, Heerden JA, MacConahey WM, Taylor WF.
Invasive Hurthle cell carcinoma of the thyroid: natural history and management.
Mayo Clinic proceedings.
1984;
59
851-855
-
8
Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J.
Follicular Hurthle cell tumors of the thyroid.
Cancer.
1991;
68
1944-1953
-
9
Shaha AR, Shah JP, Loree TR.
Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid.
American Journal of Surgery.
1996;
172
692-694
-
10
Lowe VJ, Mullan BP, Hay ID, Maclver B, Kasperbuer JL.
18F-FDG PET of patients with Hurthel cell carcinoma.
Journal of Nuclear Medicine.
2003;
44
1402-1406
-
11
Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW.
Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients.
Journal of Nuclear Medicine.
2006;
47
1260-1266
-
12
Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K.
Hurthle cell tumor of the thyroid: analysis of 188 cases.
World Journal of Surgery.
2001;
25
1160
-
13
Kushchayeva Y, Duh QY, Kebebew E, Clark OH.
Prognostic indica-tions for Hurthle cell cancer.
World Journal of Surgery.
2004;
28
1266-1270
-
14
Yutan E, Clark OH.
Hurthle cell carcinoma.
Current treatment options in oncology.
2001;
2
331-335
-
15
Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS, Ringel M, Parkerson S, Allo M, Udelsman R.
Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy.
Annals of Surgery.
1998;
227
542-546
Correspondence
S. NamwongpromMD
Department of Nuclear Medicine
Unit 1264
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Houston
77030 Texas
Phone: +1/713/792 70 31
Fax: +1/713/563 36 93
Email: snamwong@mail.med.cmu.ac.th